A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

NCT07498725 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: LRK-4189 escalation
DRUG: LRK-4189 expansion
DRUG: LRK-4189 optimization
DRUG: Chemo

Sponsor

LARKSPUR BIOSCIENCES, INC.